Two ASX healthcare shares are stealing the spotlight this week. Telix Pharmaceuticals Ltd (ASX: TLX) shares have rocketed by as much as 15%, while 4DMedical Ltd (ASX: 4DX) shares have added around 10% at the time of writing.
Here's the story behind each move, plus what brokers now expect.
Image source: Getty Images
Telix now has 3 FDA-cleared diagnostics
Telix just delivered the news investors had circled on their calendars. On Monday, the FDA approved Pixclara, Telix's PET imaging agent for brain cancer, confirming Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma.
That's a big deal. This asset had already been knocked back once, with the FDA issuing a knockback in mid-2025 over data consistency before Telix resubmitted its application and won a priority review with a September action date. Getting it over the line removes years of regulatory overhang in one shot.
This ASX healthcare share has been a rollercoaster for exactly this reason. Binary regulatory outcomes can swing the price into double digits overnight. With approval finally locked in, Telix now has three FDA-cleared products anchoring its diagnostics franchise, adding a new revenue stream to its existing prostate and kidney imaging portfolio.
Brokers were already leaning bullish before Monday's news. Consensus data shows 13 out of 16 analysts on TradingView rate Telix a buy or strong buy, with an average 12-month price target around 45% above the current share price.
Citi has been the most bullish, maintaining a $31 target, while JPMorgan sits around $24.40. Not everyone's on board. RBC downgraded to hold with an $18 target, a fraction higher than the share price at the time of writing.
4DMedical: starting to show commercial traction
4DMedical's move is smaller in percentage terms but reflects a similar theme: commercial traction finally showing up in the numbers.
The respiratory-imaging company has spent the past two years converting FDA clearances and marquee partnerships into actual revenue, and this ASX healthcare share has rewarded patient holders handsomely with a 112% gain over 12 months.
The engine for this tech stock is CT:VQ, 4DX's ventilation-perfusion imaging software, which uses ordinary chest CT scans to generate the kind of data that once required nuclear medicine.
Adoption has been building steadily across top-tier US academic centres, and Medicare has already confirmed reimbursement under Category III CPT codes. That's a crucial unlock for hospital adoption at scale.
Analysts, though, are more split on 4DMedical than on Telix. Bell Potter remains the standout bull, maintaining a $6.00 target, while Ord Minnett carries a sell at $3.00. It's a name where opinions genuinely diverge on how fast the commercial ramp will actually convert to profit.
Foolish takeaway
Both stocks are classic high-beta plays in the healthcare space. And this week's rally shows exactly why: regulatory and commercial catalysts can move these ASX healthcare shares fast in either direction.
Telix's Pixclara approval is about as clean a catalyst as it gets, and brokers have responded accordingly. 4DMedical's story is earlier-stage and more contested among analysts.
Investors chasing either move after the fact should weigh the excitement of the headline against the underlying pace of revenue growth — and size accordingly.
